S

Syndax Pharmaceuticals
D

SNDX

16.110
USD
0.52
(3.34%)
Market Closed
Volume
42,459
EPS
-3
Div Yield
-
P/E
-4
Market Cap
1,375,112,144
OverviewSignalsIdeasNews
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    176.95 USD
    AZN
    AZN
    -1.830
    (-2.81%)
    65.635 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    NVO
    NVO
    -3.620
    (-3.44%)
    105.07 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.63 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    More
News

Title: Syndax Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.